Scilex (NASDAQ:SCLX – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Scilex to similar businesses based on the strength of its dividends, earnings, valuation, profitability, analyst recommendations, risk and institutional ownership.
Volatility & Risk
Scilex has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Scilex’s peers have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.
Earnings and Valuation
This table compares Scilex and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Scilex | $31.61 million | -$358.73 million | -0.01 |
| Scilex Competitors | $18.73 billion | $3.24 billion | 560.54 |
Scilex’s peers have higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
69.7% of Scilex shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 4.5% of Scilex shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Scilex and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scilex | -1,414.57% | N/A | -147.00% |
| Scilex Competitors | -2,391.71% | -204.89% | -14.89% |
Analyst Ratings
This is a breakdown of current ratings and target prices for Scilex and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scilex | 1 | 0 | 0 | 0 | 1.00 |
| Scilex Competitors | 7870 | 13817 | 25857 | 1043 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 30.33%. Given Scilex’s peers stronger consensus rating and higher probable upside, analysts plainly believe Scilex has less favorable growth aspects than its peers.
Summary
Scilex peers beat Scilex on 9 of the 13 factors compared.
About Scilex
Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing treatments for pain and related conditions. Its portfolio includes therapies designed to offer alternatives to conventional pain-management approaches. Its marketed products include ZTlido, a topical lidocaine system for pain associated with postherpetic neuralgia; Elyxyb, an oral celecoxib solution for acute migraine in adults; and GLOPERBA, an oral colchicine solution for preventing gout flares in adults.
Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.
